The FOURIER and ARISTOTLE trials were two of the most eagerly anticipated study results presented at the ACC in Washington DC on March 17th. Dr. Bernie Monteleone, former Director of St. Francis Heart Center, reviews the outcomes of these studies and other practice impacting questions that made news at ACC this year.
FOURIER reinforces the “lower is better” LDL cholesterol hypothesis, but did adding PCKS9 inhibitor treatment to 27,564 high risk patients lead to improved clinical outcomes? Listen to Dr. Bernie’s take on the study:
Is there a safety concern using digoxin in patients with Atrial fibrillation? To better asses the drug’s safety, the ARISTOTOLE trial compared apixaban with warfarin in 18,201 patients with atrial fibrillation. Listen to the researchers’ recommendations here:
Has the tide turned for omega 3 fish oil? The American Heart Association published a new science advisory on March 13th 2017 to make clinicians aware of what’s known and not known about omega 3 fish oil and cardiovascular disease. Reductions in coronary heart disease deaths, reduced risk of total mortality, and a reduced risk of cardiovascular hospitalization were all encouraging findings…but only for patients with prior coronary heart disease or a history of heart failure. Listen to Dr. Bernie’s recommendations here:
If you’d like more information about the future of cardiology practice, please download our white paper Cardiology: Current Practice Gives Glimpse of the Future.Tags: AccessCardiology, cardiology practice, practice impact extra, cardiology, American College of Cardiology Conference 2017, ACC 2017